FDA awards nine companies priority review vouchers for expedited drug approvals
The FDA has awarded nine companies, including Regeneron and Revolution Medicines, a new 'national priority' voucher to expedite drug reviews, potentially reducing evaluation time to one or two months for treatments addressing urgent health needs, with the program currently limited to select drugs meeting specific criteria.